// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























24782 Abstracts

Association of hypermethylation at the NDRG4 CpG island with the risk of gastric cancer.

Jieer Ying - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

Methylation of CpG islands in the promoter regions of P16, hMLH1 and CDH1 genes in patients with gastric cancer.

Jieer Ying - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

Prognostic performance of lymph node staging systems in patients with resectable gastric cancer: Comparison of population-based nomograms.

Rui-hua Xu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

A novel candidate tumor suppressor and a potential prognostic biomarker, hVPS52, in gastric cancer.

Jian Zhang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

Evaluation of MET and HER2 expression in primary and metastatic tumor in Chinese advanced gastric cancer patients.

Miaozhen Qiu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

Whether preoperative enlarged lymph nodes affect long-term outcome following laparoscopic radical gastrectomy for gastric cancer? A propensity score-matched case control study.

Qiyue Chen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

Randomized controlled trials comparing clinical outcomes of 3D versus 2D laparoscopic surgery for gastric cancer: An interim report.

Changming Huang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

A retrospective comparison of taxane and fluorouracil-based chemoradiotherapy in patients with inoperable esophageal squamous cell carcinoma.

Shuiyun Han - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Fluorouracil

Effect of H3K27 acetylation activated-long noncoding RNA CCAT1 on cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous carcinoma cell.

Jinfei Chen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

N/A

Prognostic model based on immune checkpoint proteins expression and clinicopathological factors to predict outcome of patients with gastric cancer.

Ti Wen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

The potential involvement of circular RNA in the development of radiation resistance of esophageal cancer.

Huafang Su - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

N/A

Contribution of eukaryotic translation initiation factor 3B to the pathogenesis of hepatocellular carcinoma via targeting EGFR and ZAK.

Jian-Feng Zheng - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Platelet-to-hemoglobin ratio as a prognostic factor for hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization.

Xing Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Influence of age on overall survival of patients with hepatocellular carcinoma after hepatic resection.

Jian-Hong Zhong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Myeloid deprived suppressor cell to mediate the prognostic value of neutrophil for advanced hepatocellular carcinoma patients.

Xing Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Serum albumin to globulin ratio as an indicator for the prognosis for cholangiocarcinoma.

Qu Lin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

N/A

The density of cancer-associated fibroblasts as a prognostic indicator for hepatocellular carcinoma.

Tian Tian Wang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Imaging and pathological characters in pig liver after MR-guided microwave ablation.

Jun Dong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Predictive value of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) for patients with advanced HBV-associated HCC.

Zhan-Hong Chen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A CNV computational model for clonal origin analysis of synchronous multifocal hepatobiliary and pancreatic tumors.

Weiqin Jiang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Copyright © 2026. QuantiNova All rights reserved